Tarlatamab as first-line treatment in combination with carboplatin, etoposide, and PD-L1 inhibitor in patients with extensive-stage small cell lung cancer (ES-SCLC)

Kriterien zur Teilnahme
Participants will be included in the study if they meet the following criteria: - Age ≥ 18 years - Participants with histologically or cytologically confirmed ES-SCLC and no prior systemic treatment for ES-SCLC except for the first-line therapy described below. Participants with prior treatment for advanced-stage SCLC are allowed o Parts 1 to 4: The participant must have completed one cycle of platinum-based chemotherapy, etoposide, and PD-L1 inhibitor. Participants who had no access to a PD-L1 inhibitor are allowed o Parts 5 and 6: Participants must have completed 4 cycles of first-line chemotherapy with platinum, etoposide, and PD-L1 inhibitor and must not have experienced disease progression. If there is no access to a PD-L1 inhibitor for first-line treatment, patients who have received 4 to 6 cycles of platinum-based chemotherapy plus etoposide are eligible - Measurable disease according to the modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (only for Parts 1 to 4). - Individuals with treated asymptomatic brain metastases are eligible, provided they meet the following criteria o Only supratentorial and cerebellar metastases allowed o Stereotactic radiosurgery must be completed at least 7 days prior to the first planned dose of study treatment o No need for corticosteroids and no or stable doses of antiepileptics o No signs of radiological progression of the central nervous system (CNS) after definitive therapy at the time of study screening o New or asymptomatic CNS metastases discovered during screening examinations must be irradiated or surgically treated to address CNS metastases. A repeat imaging study is not required if all the above criteria are met. (BASEC)

Ausschlusskriterien
Participants will be excluded from the study if any of the following criteria are met: - Untreated or symptomatic brain metastases and/or leptomeningeal disease - History or signs of interstitial lung disease or active non-infectious pneumonitis - Diagnosis of immunodeficiency or receipt of systemic steroid therapy or another form of immunosuppressive therapy within 7 days prior to the first dose of study treatment (BASEC)